Erbitux Phase IV Studies Will Evaluate EGFR Expression As Patient Selection Criterion
This article was originally published in The Pink Sheet Daily
Executive Summary
Two of 13 total postmarketing commitments involve studying the efficacy of Erbitux in patients with EGFR-negative colorectal cancer. Other Phase IVs include a dose finding study in the pediatric population.
You may also be interested in...
Erbitux Launch Benefits From EGFR Screening, ImClone Says
Screening prospective patients for expression of epidermal growth factor receptor will positively affect Erbitux' launch, ImClone said April 27
Erbitux Launch Benefits From EGFR Screening, ImClone Says
Screening prospective patients for expression of epidermal growth factor receptor will positively affect Erbitux' launch, ImClone said April 27
Erbitux Companion Test Approval Clears Path For Further R&D Alliances
Oncologic drug/diagnostic markers show further room for co-development, as demonstrated by the pairing of the colorectal cancer drug Erbitux and DakoCytomation's EGFR pharmDx. ImClone drug reimbursement trends likely will drive uptake of the diagnostic.